

1 **The aerobiology of SARS-CoV-2 in UK hospitals and the impact of aerosol generating**
2 **procedures**

3 Susan Gould^{1*}, Rachel L Byrne^{1*}, Thomas Edwards¹, Ghaith Aljayyousi¹, Dominic Wooding¹,
4 Kate Buist¹, Konstantina Kontogianni¹, Allan Bennett², Barry Atkinson², Ginny Moore², Jake
5 Dunning³, Stacy Todd⁴, Marie-Claire Hoyle⁴, Lance Turtle⁵, Tom Solomon^{4,5,6,7}, Richard
6 Fitzgerald⁵, Mike Beadsworth⁴, Paul Garner¹, Emily R Adams¹, and Tom Fletcher^{1,4}

7 ¹Liverpool School of Tropical Medicine, Liverpool, UK.

8 ²UK Health Security Agency

9 ³University of Oxford

10 ⁴Liverpool University Hospitals NHS Foundation Trust

11 ⁵University of Liverpool

12 ⁶National Institute for Health Research Health Protection Research Unit in Emerging and
13 Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, University of
14 Liverpool

15 ⁷The Walton Centre NHS Foundation Trust

16 *authors contributed equally

17 **Running title: SARS-CoV-2 aerosols in AGP rooms (max 50 characters)**

18 **Sources of funding:** SG, EA, JD, LT, TS and TF are supported by the National Institute for Health
19 Research (NIHR) Health Protection Research Unit in Emerging and Zoonotic Infections. SG and
20 PG are supported by the READ-It (project number 300342-104) which is funded by UK aid from
21 the UK government. PhD stipend from the medical research council to RLB.

22 **Conflicts of Interest:** Emily Adams is Director of Epidemics and NTDs at Global Access diagnostics.

23 **Corresponding author:** Rachel L Byrne, Liverpool School of Tropical Medicine, Pembroke Place,
24 Liverpool UK. E-mail: Rachel.byrne@lstm.ac.uk phone number: 01517053100

25 **Keywords:** COVID-19, aerobiology, Aerosol generating procedure

26 **Word count:** Abstract, 250; Manuscript, 3047

27 **Authors' contributions:** The study was conceived by ERA, RLB, TF and SG. The study design was
28 developed by ERA, BA, AB, RLB, TE, TF, SG and GM. Data collection and extraction was
29 conducted by RLB, SG, MH. Laboratory work was completed by KB, RLB, SG, KK and DW. Data
30 analysis and interpretation were conducted by GA, BA, MB, AB, RLB, JD, TE, RF, TF, PG, SG, GM,
31 TS, ST, LT and DW. The initial manuscript was prepared by GA, RLB and SG. All authors edited
32 and approved the final manuscript.

33 **Abstract (250 words)**

34 Background

35 SARS-CoV-2 nosocomial transmission to patients and healthcare workers (HCWs) has occurred
36 throughout the COVID-19 pandemic. Aerosol generating procedures (AGPs) seemed particularly
37 risky, and policies have restricted their use in all settings. We examined the prevalence of
38 aerosolized SARS-CoV-2 in the rooms of COVID-19 patients requiring AGP or supplemental
39 oxygen compared to those on room air.

40 Methods

41 Samples were collected prospectively near to adults hospitalised with COVID-19 at two tertiary
42 care hospitals in the UK from November 2020 – October 2021. The Sartorius MD8 AirPort air
43 sampler was used to collect air samples at a minimum distance of 1.5 meters from patients. RT-
44 qPCR was used following overnight incubation of membranes in culture media and extraction.

45 Results

46 We collected 219 samples from patients' rooms: individuals on room air (n=67) , receiving
47 oxygen (n=65) or AGP (n=67). Of these, 54 (24.6%) samples were positive for SARS-CoV-2 viral
48 RNA. The highest prevalence was identified in the air around patients receiving oxygen (32.3%,
49 n=21, CI95% 22.2 to 44.3%) with AGP and room air recording prevalence of (20.7%, n=18,
50 CI95% 14.1 – 33.7%) and (22.3%, n=15, CI95% 13.5 – 30.4%) respectively. We did not detect a
51 significant difference in the observed frequency of viral RNA between interventions.

52 Interpretation

53 SARS-CoV-2 viral RNA was detected in the air of hospital rooms of COVID-19 patients, and AGPs
54 did not appear to impact the likelihood of viral RNA. Enhanced respiratory protection and
55 appropriate infection prevention and control measures are required to be fully and carefully
56 implemented for all COVID-19 patients to reduce risk of aerosol transmission.

57 **Background**

58 Since the emergence of the severe acute respiratory syndrome coronavirus (SARS-CoV-2) in
59 2019 there have been intense efforts to understand the natural history of COVID-19 disease
60 and transmission characteristics. The risk of nosocomial transmission has been well reported
61 and personal protective equipment (PPE) requirements for healthcare workers (HCWs) has
62 generated significant discussion internationally¹. The World Health Organization (WHO)
63 recently estimated that between 80 000 and 180 000 HCWs have died of COVID-19 up to May
64 2021².

65 Aerosol generating procedures (AGPs) such as non-invasive ventilation (NIV) have been
66 considered essential in providing respiratory support for patients with severe COVID-19 and in
67 reducing the need for invasive ventilation which is associated with higher morbidity and
68 mortality, others such as High Flow oxygen have now been shown to offer no benefit in
69 comparison with conventional oxygen³⁻⁵. Despite improved patient outcomes, AGPs came
70 under increased scrutiny during the severe acute respiratory syndrome (SARS) outbreak of
71 2003, when observational data suggested AGPs increased the risk of healthcare workers (HCW)
72 acquiring infection⁶. Hesitancy in adopting NIV, high flow oxygen or performing other AGPs may
73 be attributable to perceived risk to HCWs or limited availability of resources thought to be pre-
74 requisite such as negative pressure ventilation and higher-grade PPE⁷. In addition, there is a
75 lack of consensus as to what classes as an AGP and international guidelines (such as WHO, the
76 Centers for Disease Control (CDC) or UK Health Security Agency (UK HSA)) are based on expert
77 opinion due to a lack of solid evidence base.

78 Air sampling studies in healthcare settings have reported a broad range of frequencies of
79 detection of SARS-CoV-2. Multi-centre environmental sampling performed by UK HSA in 2020
80 in 8 UK hospitals identified SARS-CoV-2 RNA in 4 of 55 air samples collected <1m from patients⁸.
81 Other studies have reported rates of 0-72%^{9,10} PCR positivity in air samples. More recent
82 environmental sampling within the RECOVERY-RS (Randomised Evaluation of COVID-19
83 Therapy, Respiratory Support) study included air samples collected during administration of
84 continuous positive airways pressure (CPAP), high flow nasal oxygen (HFNO) and supplemental

85 oxygen. Of 90 air samples from 30 patients 14% were positive for at least one target on PCR and
86 no statistical difference in frequency of positivity was identified between the three groups
87 (CPAP, HFNO and other oxygen)¹¹. In healthy volunteers, two studies have demonstrated that
88 coughing, speaking or heavy breathing generate significantly higher volumes of detectable
89 respiratory particles than use of CPAP or HFNO^{12,13}.

90 However, confirmation of the significance of SARS-CoV-2 in the air in hospitalised settings has
91 not been definitive due to the absence of routine air sampling in a prospective COVID-19
92 patient cohort, with the WHO calling for further studies on the risk of SARS-CoV-2 release
93 during AGPs⁷. A range of approaches have been adopted to investigate the relative risk of
94 aerosol transmission in comparison to other modes like fomite, direct contact or close-range
95 droplet¹⁴. Further, there is a recognized need to identify which precautions would be most
96 effective in mitigating risks, to better protect communities and healthcare services including
97 vulnerable patients and staff.

98 This study addresses the question of whether there is an increased likelihood of detecting
99 aerosolized SARS-CoV-2 RNA in the rooms of COVID-19 patients undergoing AGPs than in the
100 rooms of patients requiring oxygen at flow rates of less than 15L/min via mask or nasal
101 cannulae, or not requiring any supplemental oxygen. For the purposes of this study, AGPs are
102 defined as those listed by UKHSA for which specific guidance on infection prevention and
103 control (IPC) measures is provided in the UK (UKHSA 2022)¹⁵ (Figure 1).

104 **Methods (781)**

105 **Setting**

106 Liverpool University Hospitals NHS Foundation Trust have two acute tertiary referral hospital
107 sites within Liverpool, UK (Royal Liverpool University (RLUH) and Aintree University Hospitals
108 (AUH)) that have each managed large cohorts of COVID-19 patients. CPAP, non-invasive
109 ventilation and use of high-flow oxygen were rapidly adopted as therapeutic interventions in
110 Liverpool¹⁶ but are listed as AGPs. AGPs were conducted in areas with enhanced ventilation,
111 including pre-existing negative pressure rooms, newly installed temporary systems providing

112 ventilation or areas such as theatre or intensive care. Together with UK-HSA, who had already
113 undertaken air and environmental sampling in hospitals⁸ we continued to collect air samples
114 from the rooms of patients hospitalised with COVID-19.

115 Prospective air sampling was performed around inpatients with a recent diagnosis of SARS CoV-
116 2 and in community ambulatory cases (n=13) admitted to the clinical research unit for
117 screening or treatment as part of an early phase trial. Samples included in this interim analysis
118 were collected between November 2020 and October 2021, and the dominant circulating
119 variants in the UK during this period were B.1.1.7 Alpha (PANGO lineage B.1.1.7) and Delta
120 (PANGO lineage B.1.617.2)¹⁷. Locations sampled include high dependency units, NIV units,
121 critical care units, infectious diseases, respiratory and general wards, and emergency departments.
122 No additional biological samples or clinical information were collected from the patients whose
123 rooms was sampled. No changes to behaviour or clinical care were requested from staff or
124 patients during sampling periods, staff and patients were aware that sampling was taking place.
125 Samples were categorised as either 1) room samples; patients not undergoing any respiratory
126 treatment 2) oxygen; patients undergoing oxygen at flow rates of less than 15L/min via nasal
127 cannulae/mask or 3) AGP; patients undergoing an AGP.

128 **Sample collection and processing**

129 To collect air samples, we used the Sartorius MD8 AirPort portable air sampler with gelatin
130 membranes (Sartorius, Germany). To ensure aerosols were captured and to minimize the
131 collection of large droplets, the sampler was placed at approximately 1.5 meters¹⁸ and the
132 sampler faced away from the participant. When sampling at a participant's bedside, the
133 sampler was typically placed on a hospital chair or table. At each sampling timepoint 1000L of
134 air was collected at a flow rate of 40 L/min.

135 Once completed the gelatin membrane was removed from the sampler using clean gloves, and
136 placed in a sterile 50ml Falcon tube (Corning Science, United States). Samples were transported
137 to the Biological Safety level 3 (BSL3) laboratories at the Liverpool School of Tropical Medicine
138 within 2 hours of sample collection. The gelatin membranes were immediately suspended in

139 10ml Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine solution (FBS; both
140 ThermoFisher, USA) and 50 units per ml of penicillin/streptomycin (Gibco, US). Samples were
141 vortexed and then stored overnight at 4°C to allow the membrane to fully dissolve without
142 impacting the stability of SARS-CoV-2¹⁹.

143 **RNA extraction, PCR and cell culture**

144 Following overnight storage, samples were brought to room temperature by incubation for up
145 to two hours. 140µl (1.4%) of each sample was then taken for RNA extraction. Viral RNA was
146 extracted using the QIAamp viral RNA mini kit (Qiagen, Germany) following the manufacturer's
147 instructions with an internal RT-qPCR extraction control incorporated before the lysis stage
148 (ThermoFisher, USA). Once extracted samples were taken immediately for downstream
149 application and stored at 4°C during PCR setup.

150 For SARS-CoV-2 RT-qPCR detection, 10µl of extracted RNA was tested using the TaqPath™
151 COVID-19 CE-IVD RT-PCR assay (ThermoFisher, USA) that detects three different SARS-CoV-2
152 genomic regions (ORF1ab, N gene, S gene), on the QuantStudio 5 platform (ThermoFisher,
153 USA). The PCR was deemed to be positive if one SARS-CoV-2 target and the internal control
154 amplified, this differs from the manufacturer instructions whereby two SARS-CoV-2 targets
155 must amplify however this is for clinical samples rather than for environmental samples. We do
156 not infer viability of the viral RNA we detected and thus the presence/absence of viral RNA is
157 recorded here. In instances of low Ct values the third target can often be out competed and
158 thus viral load calculations have not been appropriate using this assay. Samples were negative if
159 only the internal extraction control amplified.

160 Cell culture was attempted using a methodology adapted from Edwards *et al*²⁰. For samples
161 identified as the Alpha variant, based on S gene deletion, a 5-day incubation post inoculation
162 was used due to the variant's slower growth rate and smaller plaque sizes in Vero E6 cells²¹.
163 For all other samples a 3-day post inoculation incubation was utilized, as is routine laboratory
164 procedure. After three passage events, samples were fixed with 10% formalin, stained using
165 crystal violet and visually inspected for viral plaques.

166 **Statistical Analysis**

167 All data handling and manipulation was performed through R 3.6.3²². Binomial generalized
168 linear models (GLM) were performed to assess the ability of procedure to detect a positive
169 result, with time since infection, cycle threshold (Ct) value and location of patient included as
170 co-variates. Chi-Square test was performed to estimate the effect of procedure on detecting a
171 positive result in isolation from other factors. Additionally one-way ANOVA tests were
172 performed to assess quantitative differences between Ct values among different methods for
173 each gene.

174 **Ethics and Approvals**

175 This study was performed in conjunction with UK HSA as part of the COVID-19 clinical response.
176 In line with UK Health Resource Authority guidance this was performed as a service evaluation
177 and consisted of environmental sampling and simplified and anonymized routinely collected
178 patient information. The environmental sampling process was explained to patients and verbal
179 consent obtained.

180 **Results (450)**

181 A total of 219 air samples were collected during this study from bed spaces of 199 individuals
182 (with some patient sampled at more than one timepoint) either on room air only (n=67),
183 receiving supplemental oxygen (n=65) or undergoing an AGP (n=87) (Table 1). The median
184 number of days since onset of symptoms was 7 (Table 2). In total, 24.7% (n=55, CI95% 19.4-
185 30.8%) were positive for SAR-CoV-2 viral RNA (Appendix 1). The highest prevalence was
186 identified in the air around patients who were receiving oxygen (32.3%, n=21, CI95% 22.2 to
187 44.3%) with AGP and room air recording prevalence of 20.7% (n=18, CI95% 14.1 – 33.7%) and
188 22.3% (n=15, CI95% 13.5 – 30.4%) respectively, as shown in figure 2. The likelihood of a sample
189 being PCR positive was not influenced by procedure (GLM, $p > 0.05$).

190 We did not detect a difference in Ct values for positive samples between procedure ($p > 0.05$,
191 one-way ANOVA), shown in figure 2. We observed a reduced detection of S gene, indicative of

192 Alpha variant presence, compared to other RT-qPCR genomic targets (ORF1 and N gene). Mean
193 Ct values for AGPs, Oxygen and Room air were 32.18, 33.08 and 33.88 respectively and cell
194 culture for each sample was negative.

195 We did not detect an effect of the number of days since reported onset of symptoms and the
196 frequency of detection of viral RNA or Ct values (GLM, $P > 0.05$). Further, no association
197 between RT-qPCR results and sampling location e.g., emergency department or critical care unit
198 was identified (GLM, $p > 0.05$). Of note, there was no obvious difference in positive results for
199 the Oxygen or Room air groups when sampling in standard ventilation areas rather than
200 enhanced ventilation areas (RR in Oxygen group 1.22, RR in Room Air group 1.08) (Table 3).

201 An additional 16 air samples were taken in areas either occupied or used by patients with
202 confirmed SARS-CoV-2 infection (e.g. bathroom, nursing station), or directly adjacent i.e.
203 considered to be at risk of contamination (appendix 1), SARS-CoV-2 RNA was detected in 5 of
204 these. Culture was negative, and fungal overgrowth was noted in the bathroom samples. Of 4
205 samples collected in shared patient bathrooms 2 were RNA positive, as were 2 of 8 collected at
206 nursing stations, the remaining positive sample was collected in an ITU bay. Five of the nursing
207 station samples were from stations within 'red' zones, 1 from an area adjacent to a red zone,
208 and 2 from ward nursing stations more than 3 metres from COVID-19 patient rooms with
209 separating doors. The Ct values of these 5 samples ranged from 22.4 (S gene) at a nursing
210 station where sample was positive for all 3 genes tested, to 35.19 (for only one gene) for the
211 second positive nursing station sample and patient bathrooms. The positive sample collected in
212 a COVID-19 bay (with the nearest patient intubated) was positive for N gene and ORF1 genes.

213 **Discussion**

214 The factors that facilitate nosocomial transmission of SARS-CoV-2 remain incompletely
215 understood, including any additional risks posed by AGPs. To improve understanding and
216 inform IPC recommendations we have undertaken the largest air sampling study for SARS-Cov-2
217 published to date. In this report we provide evidence for the presence of SARS-CoV-2 viral RNA
218 isolated from the air of clinical environments in UK hospitals. In line with previous reports^{23,24},
219 we found Ct values to be high (typically above 30), indicative of low viral loads present. We did

220 not record any significant difference in the observed frequency of viral RNA detection nor viral
221 load between different procedures being undertaken including AGPs. Interestingly, we did
222 observe higher positivity rates in individuals receiving oxygen (flow rates of less than 15L/min
223 via nasal cannulae) than either AGP patients or those without supplementary oxygen although
224 not statistically significant.

225 The viral dynamics of SARS-CoV-2 in human disease is now well reported with higher viral loads
226 and transmission risk predominantly occurring earlier in disease course. Commonly used AGPs
227 such as CPAP are usually required later in the clinical course with median time from onset of
228 symptoms to development of respiratory failure being 8-12 days²⁸. However, we did not see a
229 significant relationship between time since symptom onset and likelihood of viral RNA
230 detection. Infective SARS-CoV-2 virus is rarely identified from clinical samples beyond 9 days
231 from onset of symptoms²⁶ and thereby chances of capturing viable virus may be confounded.
232 We were unable to culture samples, likely due to the high Ct values observed, dilutional effect
233 and due to the challenges in culturing virus after potential desiccation during the methods of air
234 sampling. Two reports describe the isolation of infectious SARS-CoV-2 from air sampling.
235 Lednicky *et al* describe isolation of SARS-CoV-2 virus from hospital rooms used by 2 patients
236 and a vehicle occupied by an infected individual with sequencing of cultured virus matching
237 that of the cases sampled^{27,28}. Another challenge in isolating virus from air samples was
238 identified by Lednicky *et al* as another respiratory virus was found to potentially overgrow
239 SARS-CoV-2 in culture²⁷. Santarpia *et al* described cytopathic effect (CPE), suggested increase in
240 RNA titre on days 3 and 4 of culture and presence of viral proteins on immunofluorescent
241 staining in 1 air sample but could not confirm cultivation of virus²⁴. Published aerobiology
242 studies in healthcare settings use a wide array of methods such as filtering air through gelatin,
243 PTFE or PC membranes, using liquid cyclonic sampling such as the Coriolis (Bertin), or impaction
244 e.g., Anderson samplers (Appendix 2). Sampling distances from specified patients sampled
245 varied from 10cm to 3m. Lednicky *et al* utilised a water condensation collection method (VIVAS)
246 and Santarpia the Sartorius MD8 airport sampler with gelatin membrane filters^{24,27}. The
247 diversity of study design and equipment as well as processing and analytical methods presents
248 challenges in comparing the results of different studies. Less than 10 air sampling studies

249 identified through literature search have reported attempted cell culture^{10,11,27,29–31}, and the
250 majority have been unable to confirm presence of viable virus despite detection of SARS CoV-2
251 RNA through PCR^{11,29,31}. This is likely attributable to the insensitivity of cell culture, which
252 requires a large inoculum and represents an imperfect model of infection of the human
253 nasopharynx. These challenges are increased when considering environmental samples with
254 low concentrations of detectable viral RNA and the degree of dilution involved in air sampling
255 methods including our own.

256 It is now accepted that a spectrum of expelled sizes of respiratory particles exist with risk of
257 infection dependent on additional key factors. These include variables relating to the person
258 (e.g., symptoms, duration of illness, individual variation in respiratory particle dispersion) and
259 those related to place (e.g., ventilation, proximity to susceptible individuals) that may be
260 equally or more important than the procedures undertaken. As this was a pragmatic
261 environmental sampling study, detailed patient level data and correlation with clinical SARS
262 CoV-2 samples was not available. This is a recognized limitation as individual characteristics and
263 the viral load detectable on clinical samples may impact likelihood of detection of viral RNA or
264 viable virus in the environment. AGPs were conducted in negative pressure single rooms, pods
265 or bays and bronchoscopy or endoscopy in designated facilities in accordance with Health
266 Technical memorandum 03-01 (including minimum 10 air changes per hour). Those on room air
267 or oxygen were more commonly cared for in rooms with neutral pressure. We also recognise
268 that multiple factors affect the potential impact of infective aerosols including temperature,
269 humidity and ventilation, patient and staff behaviour and pre-existing natural or vaccine
270 mediated immunity.

271 This study adds to the data of air sampling studies conducted within hospitals caring for COVID-
272 19 patients and offers reassurances to HCW performing AGPs that the presence of SARS-CoV-2
273 in the air is no different compared with environments where no AGPs are taking place. Our data
274 supports the conclusions drawn from the recent exploratory air sampling study conducted on
275 30 participants within the RECOVERY RS trial in which CPAP, HFNO and supplementary oxygen

276 via venturi were compared. The observed frequency of detection was not significantly higher in
277 the AGP groups¹¹.

278 Internationally differing lists of AGPs have been produced e.g. including or excluding nebulized
279 therapies or cardiopulmonary resuscitation. In the UK the expert panel responsible for
280 formulating such a list assessed the available evidence as ‘poor quality’¹⁵. AGPs vary widely and
281 more sampling around a broader range of procedures is required to establish whether there is
282 any evidence of increased risk associated. Any reduction in protections for potentially
283 vulnerable staff or patients regarding AGPs would require more certainty which could only be
284 provided by a more comprehensive evidence base. As we move towards endemicity of COVID-
285 19, it remains imperative to protect HCW and vulnerable patients from nosocomial infections.
286 Appropriate PPE and mask use are essential as SARS-CoV-2 is frequently detectable in the air
287 surrounding positive patients. We believe our data supports the use of FFP2/3 medical masks
288 for HCWs caring for COVID-19 patients, particularly for those with prolonged contact in line
289 with HSE guidelines ¹⁵. As we move forwards, we must continue to avoid oversimplifying the
290 transmission dynamics of SARS-CoV-2 including into ‘droplet vs aerosol’, as this can lead to
291 fixed IPC recommendations and must now appreciate that the ‘person, place and procedure’
292 influence transmission risk. Future recommendations must be guided by emerging evidence
293 including ongoing studies to identify transmission differences that may occur with new variants
294 of concern.

295 **Role of the funding source**

296 The study funders had no influence over the design, conduct, analysis and interpretation of the
297 study; nor the writing of the report and the decision to submit the paper for publication.

298 References

- 299 1 Thomas JP, Srinivasan A, Wickramarachchi CS, Dhesi PK, Hung YMA, Kamath A V.
300 Evaluating the national PPE guidance for NHS healthcare workers during the COVID-19
301 pandemic. *Clin Med J R Coll Physicians London* 2020; **20**: 242–7.
- 302 2 World Health Organisation. Health and Care Worker Deaths during COVID-19. 2021.
303 [https://www.who.int/news/item/20-10-2021-health-and-care-worker-deaths-during-](https://www.who.int/news/item/20-10-2021-health-and-care-worker-deaths-during-covid-19)
304 [covid-19](https://www.who.int/news/item/20-10-2021-health-and-care-worker-deaths-during-covid-19) (accessed Oct 21, 2021).
- 305 3 Wozniak DR, Rubino A, Tan AL, *et al.* Positive role of continuous positive airway pressure
306 for intensive care unit patients with severe hypoxaemic respiratory failure due to COVID-
307 19 pneumonia: A single centre experience. *J Intensive Care Soc* 2022; **23**: 27–33.
- 308 4 Ashish A, Unsworth A, Martindale J, *et al.* CPAP management of COVID-19 respiratory
309 failure: A first quantitative analysis from an inpatient service evaluation. *BMJ Open Respir*
310 *Res* 2020; **7**: e000692.
- 311 5 Perkins GD, Ji C, Connolly BA, *et al.* Effect of Noninvasive Respiratory Strategies on
312 Intubation or Mortality among Patients with Acute Hypoxemic Respiratory Failure and
313 COVID-19: The RECOVERY-RS Randomized Clinical Trial. *JAMA - J Am Med Assoc* 2022;
314 **327**: 546–58.
- 315 6 Judson SD, Munster VJ. Nosocomial transmission of emerging viruses via aerosol-
316 generating medical procedures. *Viruses*. 2019; **11**. DOI:10.3390/v11100940.
- 317 7 Diaz, Janet; Appiah, John; Askie, Lisa; Baller, April; Banerjee, Anshu; Barkley, Shannon;
318 Bertagnolio, Silvia; Hemmingsen, Bianca; Bonet, Mercedes; Cunningham J. COVID-19 :
319 Clinical management Living guidance. 2021
320 <https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1> (accessed
321 Sept 6, 2021).
- 322 8 Moore G, Rickard H, Stevenson D, *et al.* Detection of SARS-CoV-2 within the healthcare

- 323 environment: a multi-centre study conducted during the first wave of the COVID-19
324 outbreak in England. *J Hosp Infect* 2021; **108**: 189–96.
- 325 9 Li YH, Fan YZ, Jiang L, Wang HB. Aerosol and environmental surface monitoring for SARS-
326 CoV-2 RNA in a designated hospital for severe COVID-19 patients. *Epidemiol Infect* 2020.
327 DOI:10.1017/S0950268820001570.
- 328 10 Ang AXY, Luhung I, Ahidjo BA, *et al.* Airborne SARS-CoV-2 surveillance in hospital
329 environment using high-flowrate air samplers and its comparison to surface sampling.
330 *Indoor Air* 2021; : 1–10.
- 331 11 Winslow RL, Zhou J, Windle EF, *et al.* SARS-CoV-2 environmental contamination from
332 hospitalised patients with COVID-19 receiving aerosol-generating procedures. *Thorax*
333 2021; : thoraxjnl-2021-218035.
- 334 12 Wilson NM, Marks GB, Eckhardt A, *et al.* The effect of respiratory activity, non-invasive
335 respiratory support and facemasks on aerosol generation and its relevance to COVID-19.
336 *Anaesthesia* 2021; **76**: 1465–74.
- 337 13 Hamilton FW, Gregson F, Arnold DT, *et al.* Aerosol emission from the respiratory tract: an
338 analysis of relative risks from oxygen delivery systems. *medRxiv* 2021; :
339 2021.01.29.21250552.
- 340 14 Nissen K, Krambrich J, Akaberi D, *et al.* Long-distance airborne dispersal of SARS-CoV-2 in
341 COVID-19 wards. *Sci Rep* 2020; **10**: 1–9.
- 342 15 UKHSA. Infection prevention and control for seasonal respiratory infections in health and
343 care settings (including SARS-CoV-2) for winter 2021 to 2022. Updated 17 January 2022.
344 2022. [https://www.gov.uk/government/publications/wuhan-novel-coronavirus-](https://www.gov.uk/government/publications/wuhan-novel-coronavirus-infection-prevention-and-control/covid-19-guidance-for-maintaining-services-within-health-and-care-settings-infection-prevention-and-control-recommendations#transmission-based-precautions)
345 [infection-prevention-and-control/covid-19-guidance-for-maintaining-services-within-](https://www.gov.uk/government/publications/wuhan-novel-coronavirus-infection-prevention-and-control/covid-19-guidance-for-maintaining-services-within-health-and-care-settings-infection-prevention-and-control-recommendations#transmission-based-precautions)
346 [health-and-care-settings-infection-prevention-and-control-](https://www.gov.uk/government/publications/wuhan-novel-coronavirus-infection-prevention-and-control/covid-19-guidance-for-maintaining-services-within-health-and-care-settings-infection-prevention-and-control-recommendations#transmission-based-precautions)
347 [recommendations#transmission-based-precautions.](https://www.gov.uk/government/publications/wuhan-novel-coronavirus-infection-prevention-and-control/covid-19-guidance-for-maintaining-services-within-health-and-care-settings-infection-prevention-and-control-recommendations#transmission-based-precautions)

- 348 16 Nightingale R, Nwosu N, Kutubudin F, *et al.* Is continuous positive airway pressure (CPAP)
349 a new standard of care for type 1 respiratory failure in COVID-19 patients? A
350 retrospective observational study of a dedicated COVID-19 CPAP service. *BMJ Open*
351 *Respir Res* 2020; **7**: 8–10.
- 352 17 Hadfield J, Megill C, Bell SM, *et al.* NextStrain: Real-time tracking of pathogen evolution.
353 *Bioinformatics* 2018; **34**: 4121–3.
- 354 18 World Health Organization. Modes of transmission of virus causing COVID-19:
355 implications for IPC precaution recommendations. *Geneva World Heal Organ* 2020; : 19–
356 21.
- 357 19 Chin AWH, Chu JTS, Perera MRA, *et al.* Stability of SARS-CoV-2 in different environmental
358 conditions. *The Lancet Microbe* 2020; **1**: e10.
- 359 20 Edwards T, Kay GA, Aljanyoussi G, *et al.* SARS-CoV-2 Transmission Risk from sports
360 Equipment (STRIKE). *medRxiv* 2021; : 2021.02.04.21251127.
- 361 21 Jeong GU, Yoon GY, Moon HW, *et al.* Comparison of plaque size, thermal stability, and
362 replication rate among SARS-CoV-2 variants of concern. *Viruses* 2022; **14**: 4–8.
- 363 22 R Core Team. R: A language and environment for ## statistical computing. 2017.
- 364 23 Chia PY, Coleman KK, Tan YK, *et al.* Detection of air and surface contamination by SARS-
365 CoV-2 in hospital rooms of infected patients. *Nat Commun* 2020; **11**.
366 DOI:10.1038/s41467-020-16670-2.
- 367 24 Santarpia JL, Rivera DN, Herrera VL, *et al.* Aerosol and surface contamination of SARS-
368 CoV-2 observed in quarantine and isolation care. *Sci Rep* 2020; **10**. DOI:10.1038/s41598-
369 020-69286-3.
- 370 25 Li X, Ma X. Acute respiratory failure in COVID-19: Is it ‘typical’ ARDS? *Crit Care* 2020; **24**:
371 1–5.

- 372 26 Cevik M, Kuppalli K, Kindrachuk J, Peiris M. Virology, transmission, and pathogenesis of
373 SARS-CoV-2. *BMJ* 2020; **371**: 1–6.
- 374 27 Lednicky JA, Lauzard M, Fan ZH, *et al.* Viable SARS-CoV-2 in the air of a hospital room
375 with COVID-19 patients. *Int J Infect Dis* 2020; **100**: 476–82.
- 376 28 Lednicky JA, Lauzardo M, Alam MM, *et al.* Isolation of SARS-CoV-2 from the air in a car
377 driven by a COVID patient with mild illness. *Int J Infect Dis* 2021; **108**: 212–6.
- 378 29 Zhou J, Otter JA, Price JR, *et al.* Investigating Severe Acute Respiratory Syndrome
379 Coronavirus 2 (SARS-CoV-2) Surface and Air Contamination in an Acute Healthcare
380 Setting During the Peak of the Coronavirus Disease 2019 (COVID-19) Pandemic in
381 London. *Clin Infect Dis* 2021; **73**: e1870–7.
- 382 30 Binder RA, Alarja NA, Robie ER *et al.* Environmental and aerosolized severe acute
383 respiratory syndrome coronavirus 2 among hospitalized coronavirus disease 2019
384 patients. *J Infect Dis* 2020; **222**: 1798–806.
- 385 31 Dumont-Leblond N, Veillette M, Mubareka S, *et al.* Low incidence of airborne SARS-CoV-
386 2 in acute care hospital rooms with optimized ventilation. *Emerg Microbes Infect* 2020; **9**:
387 2597–605.
- 388
- 389

390 **Research in Context**

391 **Evidence before this study**

392 We searched Pubmed (Medline, Web of science (Science citation index-Expanded and Biosis) and
393 Embase for air sampling studies published between January 2020 and November 2021. Selected
394 search terms were “COVID-19”, “SARS-Cov-2”, “air sampler”, “indoor air quality”, “bioaerosol”
395 and “indoor airborne” with 326 results. Studies in which healthcare environments occupied by
396 SARS-CoV-2 infected humans were sampled were eligible. After screening of abstracts and then
397 full texts 37 papers were included.

398 Frequency of detection of viral RNA in air samples collected from COVID-19 patients varied widely
399 from 0% to 100% and factors affecting likelihood of positivity were not consistently identified.
400 Whilst isolation of infectious virus from air samples is not always attempted, it has only been
401 reported twice but this reflect the challenges of fragile virus capture. Laboratory studies have
402 demonstrated that SARS-CoV-2 may persist for several hours in airborne particles, and
403 epidemiological research has illustrated probable airborne transmission of COVID-19 in settings
404 such as restaurants. Observational data from the SARS-CoV-1 epidemic suggested that aerosol
405 generating procedures (AGPs) presented a greater transmission hazard than other care, that
406 required enhanced respiratory protection. Winslow et al recently reported that in a cohort of 30
407 patients, that AGPs were not associated with increased likelihood of SARS-CoV-2 viral RNA
408 detection in air compared to supplemental oxygen use. Studies of aerosol generation from
409 procedures such as CPAP and high flow oxygen on healthy volunteers in controlled environments
410 had predicted a low risk of airborne transmission related to such procedures in comparison to
411 cough, speech or singing.

412 **Added value of this study**

413 As the largest study to date to investigate SARS CoV-2 RNA detection in air samples from rooms
414 of patients undergoing different interventions including AGPS this study contributes significantly
415 to the limited evidence base in this area. We demonstrated that there was no greater frequency
416 of detection of SARS-CoV-2 from the environment of patients undergoing AGPs compared to
417 those on room air or oxygen. This suggests that the risk of aerosol transmission may be equally
418 significant in all areas where COVID-19 patients are cared for and appropriate respiratory

419 precautions should be recommended. This important evidence can provide data to support
420 infection prevention and control guidance in health care settings and inform risk assessments
421 and the use of AGPs in all settings.

422

423 **Implications of all available evidence**

424 SARS CoV-2 virus has been identified in the air in a range of healthcare settings where COVID-19
425 patients are managed. Our findings in combination with those reported by Winslow et al suggest
426 that AGPs do not present a uniformly increased transmission risk. Increased understanding of the
427 natural history of COVID-19 and transmission characteristics of SARS-CoV-2, promote a move
428 from the binary categories of AGP vs non-AGP for respiratory protection, towards a risk
429 assessment based primarily on the Patient and Place, as opposed to just the procedure.

430 Appendix 1: Details of positive samples

431

432 Positive samples - procedure, ventilation and Ct values

Ventilation: Negative pressure (ets. 12 ACH), Neutral or standard ward ventilation (est 6 ACH), ITU and theatre (est. 10 ACH)	Procedure: narrower categories	PCR result	N gene	S gene	ORF1
Negative	High flow	Positive	Negative	20.87	Negative
Negative	CPAP	Positive	32.16	Negative	38.35
Negative	CPAP	Positive	26.48	35.34	20.05
Neutral	Room air	Positive	Negative	38.76	25.37
Neutral	Room air	Positive	37.96	Negative	38.16
ITU	CPAP	Positive	Negative	Negative	37.65
Negative	Nasal cannulae	Positive	34.83	Negative	Negative
Negative	Room air	Positive	34.43	38.45	32.14
Negative	CPAP	Positive	38.46	Negative	Negative
Neutral	rebreath mask	Positive	28.53	Negative	Negative
Neutral	Room air	Positive	33.17	Negative	Negative
Neutral	Nasal cannulae	Positive	33.03	Negative	Negative
Neutral	Room air	Positive	34.05	negative	34.16
Neutral	Venturi mask	Positive	32.25	Negative	34.71
Neutral	Nasal cannulae	Positive	36.78	Negative	36.13
Neutral	Nasal cannulae	Positive	32.32	Negative	Negative
Neutral	NK	Positive	34.7	Negative	35.91
Negative	CPAP	Positive	Negative	Negative	37.51
Negative	CPAP	Positive	Negative	Negative	22.79
Negative	Venturi mask	Positive	35.31	Negative	Negative
Neutral	NK	Positive	32.52	Negative	33.04
Negative	Nasal cannulae	Positive	30.94	23.96	33.57
Negative	CPAP	Positive	Negative	Negative	33.4
Theatre	Endoscopy	Positive	Negative	32.97	19.39
Negative	Nasal cannulae	Positive	negative	27.7	Negative
Negative	Intubation	Positive	28.66	Negative	28.88
Negative	CPAP	Positive	28.9	Negative	Negative
Negative	Venturi mask	Positive	24.89	32.5	22.17
NK	Nasal cannulae	Positive	Negative	Negative	33.41
Neutral	Room air	Positive	Negative	20.47	Negative
Neutral	Room air	Positive	38.57	Negative	Negative
Neutral	Room air	Positive	33.47	Negative	36.14
Negative	CPAP	Positive	34.65	Negative	Negative
Negative	NK	Positive	35.73	Negative	Negative
NK	Venturi mask	Positive	35.18	Negative	Negative
Negative	CPAP	Positive	37.65	negative	negative
Negative	Venturi mask	Positive	38.41	Negative	36.17
Neutral	Room air	Positive	35.05	Negative	35.45
Negative	Room air	Positive	35.24	negative	negative
Negative	High flow	Positive	36.52	negative	negative
Negative	High flow	Positive	36.5	negative	negative
Neutral	Room air	Positive	32.53	negative	negative
Neutral	Room air	Positive	Negative	Negative	36.46
Theatre	Bronchoscopy	Positive	negative	negative	38.41
Theatre	Bronchoscopy	Positive	negative	negative	37.73
Negative	Room air	Positive	34.21	negative	negative
Negative	Room air	Positive	21.52	Negative	39.57
Negative	Room air	Positive	negative	negative	34
Negative	Venturi mask	Positive	35.29	Negative	35.78
Neutral	Venturi mask	Positive	31.07	Negative	35.54
Negative	CPAP	Positive	30.43	Negative	35.48
Negative	Venturi mask	Positive	36.01	Negative	36.4
Neutral	Nasal cannulae	Positive	32.41	Negative	34.4
Negative	Venturi mask	Positive	32.96	Negative	Negative

433

434 NK Not known CPAP Continuous positive airway pressure

435

436 **Details of samples from other areas**

Ventilation: Negative pressure (est. 12 ACH), Neutral or standard ward ventilation (est. 6 ACH), ITU and theatre (est. 10 ACH)	Setting	Area directly occupied or used by ISARS CoV-2 infected patients	PCR result	N gene	S gene	ORF1
ITU	Intubated patient	Yes	Positive	34.07	Negative	34.6
Neutral	Bathroom	Yes	Negative	Negative	Negative	Negative
Neutral	Bathroom	Yes	Positive	Negative	Negative	33.35
Neutral	Bathroom	Yes	Positive	34.89	Negative	Negative
Neutral	Bathroom	Yes	Negative	Negative	Negative	Negative
Negative	Nurses station	Yes	Negative	Negative	Negative	Negative
Negative	Nurses station	Yes	Negative	Negative	Negative	Negative
Negative	Near air vent	No	Negative	Negative	Negative	Negative
Negative	Nurses station	No	Positive	23.72	22.4	33.57
Negative	Centre of bay	No	Negative	Negative	Negative	Negative
Negative	Centre of bay	No	Negative	Negative	Negative	Negative
Negative	Nurses station	Yes	Negative	Negative	Negative	Negative
Negative	Nurses station	Yes	Negative	Negative	Negative	Negative
Negative	Nurses station	Yes	Negative	Negative	Negative	Negative
Negative	Nurses station	No	Negative	Negative	Negative	Negative
Negative	Nurses station	No	Positive	35.19	negative	negative

437

438

439 Appendix 2: Review of previous air sampling studies

440 **Summary of previous air sampling studies in healthcare settings which included details of**

441 **sampling around aerosol generating procedures (AGPs)**

Country	Number of samples, individuals (if applicable) and results of PCR and culture (if applicable)						AGPs and PCR	
	No. samples	No. patients	Air samples PCR positive/suspect	Proportion patients with >=1 positive sample	Culture attempted (Y/N)	Evidence of viable virus described	Description of AGPs	Proportion PCR positive (AGPs)
UK (refs)	4	4	2/4	NK	Y	N	Tracheostomy (3), HFNO (1)	2 (4)
USA	15	15	0/15	0(15)	N	N	BiPAP (2), HFNO (3)	0(5)
Israel	4	NK	1/4	n/a	N	N	>1 patient on high flow	1(1)
S Korea	6	3	0/6	0(3)	N	N	HFNO (1)	0(1)
Hong Kong	6	6	0/6	0(6)	N	N	HFNO (1)	0(1)
China	12	12	1/12	1(12)	N	N	intubation	1(1)
UK	90	30	14/90	9 (30)	Y	N	HFNO (30), CPAP (30)	9(60)

442 **PCR** polymerase chain reaction, **NK** not known, **n/a** not applicable, **HFNO** high flow nasal

443 oxygen, **CPAP** continuous, **AGP** Aerosol generating procedure

444

445 **Summary of air sampling conducted** 1) around specified numbers of SARS-CoV-2 infected patients, 2)
 446 around unspecified numbers of infected patients and 3) in areas not occupied by COVID-19 patients
 447 from studies where infected patients were also sampled

			Number of samples, individuals (if applicable) and results of PCR and culture (if applicable)						
			Country	No. samples	No. patients	Proportion air samples PCR positive/suspect (all)	Proportion patients with >=1 positive sample	Culture attempted (Y/N)	Evidence of viable virus described
Sampling around specified number of COVID-19 infected patients	Hospital or clinic	Ong 2020	Singapore	6	3	0 (6)	0 (3)	N	N
		Semelka 2021	USA	78	26		0 (26)	N	N
		Ong 2021	Singapore	12	19	6 (12)	NK	Y	N
		Wei 2020	China	34	9	0 (34)	0/9	N	N
		Binder 2020	USA	195	20	3(195)	3(20)	Y	N
		Guo 2020	China	48	39	15 (48)	NK	N	N
		Lednicky 2020	USA	4	2	4(4)	NK	Y	Y
		Faridi 2020	Iran	10	44	0(10)	NK (0)	N	N
		Dumont-Leblond	Canada	100	22	11(100)	6(22)	Y	N
		Dubey 2021	India	24	12	17(24)	12 (12) at 1m, 5	N	N
		Chia 2020	Singapore	22 pooled into 4	3	2(4)	2(3)	N	N
		Bokharai-Salim	Iran	14	16	0(14)	NK	N	N
		Baboli 2021	Iran	29	25	4(29)	NK	N	N
		Santarpia 2020	USA	19	11	11(19)	8(11)	Y	Y
		Razzini 2020	Italy	2	3	2(2)	NK	N	N
		Li 2020	China	14	9	2(14)	1(9)	N	N
		Lei 2020	China	36	20	0(36)	NK	N	N
		Jin 2021	China	1	1	1(1)	1(1)	N	N
		Quarantine facility or hotel	Ong 2021	Singapore	9	90	1 (9)	NK	Y
	Ben-Shmuel 202		Israel	1	1	1(1)	1(1)	N	N
Sampling around unspecified number of COVID-19 patients	Hospital/clinic	Zhou 2020	UK	22	n/a	11 (22)	n/a	Y	N
		Yuan 2020	China	32	n/a	0(32)	NK	N	N
		Lednicky 2020	USA	2	NK	1(2)	n/a	Y	Y
		Li 2020	China	36	NK	0(36)	n/a	N	N
		Masoumbeigi 20	Iran	30	NK	0(30)	NK	N	N
		Kenarkoohi 2020	Iran	11	NK	2(11)	NK	N	N
		Hernandez 2021	Mexico	10	n/a	3(10)	NK	N	N
		Yuan 2020	China	11	n/a	8 (11)	NK	N	N
		Ang 2021	Singapore	27	NK (wards full)	13(27)	NK	Y	N
		Barbieri 2021	Italy	6	NK	3 (6)	NK	N	N
		Dubey 2021	India	6	NK	5(6)	NK	N	N
		Hemati 2021	Iran	35	NK	5(35)	NK	N	N
		Grimalt 2021	Spain	11	NK	11 (11)	NK	N	N
		Sampling in areas not directly occupied by infected individuals	Hospital/clinic or quarantine facility	Ong 2020	Singapore	4	n/a	0 (4)	
Zhou 2020	UK			5	n/a	1 (5)			
Yuan 2020	China			58	n/a	0 (58)			
Li 2020	China			99	n/a	0(99)			
Masoumbeigi 20	Iran			1	n/a	0(1)			
Guo 2020	China			66	n/a	1 (66)			
Kenarkoohi 2020	Iran			3	n/a	0 (3)			
Lane 2021	USA			528	n/a	0(528)			
Tan 2020	China			17	n/a	0(17)			
Ben-Shmuel 202	Israel			1	n/a	0(1)			
Hemati 2021	Iran			10	n/a	1(10)			
Grimalt 2021	Spain			36	n/a	21 (36)			
Baboli 2021	Iran			22	n/a	2 (22)			
Dubey 2021	India			12	n/a	0(12)			
Yuan 2020	China			24	n/a	14(24)			
Santarpia 2020	USA			16	n/a	11(16)			
Razzini 2020	Italy			3	n/a	0(3)			
Jin 2020	China			1	n/a	0(1)			
Lei 2020	China			99	n/a	0(99)			